229 related articles for article (PubMed ID: 21119625)
1. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer.
Salido E; Rodriguez-Pena M; Santana A; Beattie SG; Petry H; Torres A
Mol Ther; 2011 May; 19(5):870-5. PubMed ID: 21119625
[TBL] [Abstract][Full Text] [Related]
2. Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type-1.
Jiang J; Salido EC; Guha C; Wang X; Moitra R; Liu L; Roy-Chowdhury J; Roy-Chowdhury N
Transplantation; 2008 May; 85(9):1253-60. PubMed ID: 18475180
[TBL] [Abstract][Full Text] [Related]
3. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1.
Kukreja A; Lasaro M; Cobaugh C; Forbes C; Tang JP; Gao X; Martin-Higueras C; Pey AL; Salido E; Sobolov S; Subramanian RR
Nucleic Acid Ther; 2019 Apr; 29(2):104-113. PubMed ID: 30676254
[TBL] [Abstract][Full Text] [Related]
4. Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer.
Salido EC; Li XM; Lu Y; Wang X; Santana A; Roy-Chowdhury N; Torres A; Shapiro LJ; Roy-Chowdhury J
Proc Natl Acad Sci U S A; 2006 Nov; 103(48):18249-54. PubMed ID: 17110443
[TBL] [Abstract][Full Text] [Related]
5. Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1.
Castello R; Borzone R; D'Aria S; Annunziata P; Piccolo P; Brunetti-Pierri N
Gene Ther; 2016 Feb; 23(2):129-34. PubMed ID: 26609667
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of liver and kidney proteins in a mouse model for primary hyperoxaluria type I.
Hernández-Fernaud JR; Salido E
FEBS J; 2010 Nov; 277(22):4766-74. PubMed ID: 20977670
[TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of a novel rat model of primary hyperoxaluria type 1 with a nonsense mutation in alanine-glyoxylate aminotransferase gene.
Li Y; Zheng R; Xu G; Huang Y; Li Y; Li D; Geng H
Am J Physiol Renal Physiol; 2021 Mar; 320(3):F475-F484. PubMed ID: 33491567
[TBL] [Abstract][Full Text] [Related]
8. Generation of a Primary Hyperoxaluria Type 1 Disease Model Via CRISPR/Cas9 System in Rats.
Zheng R; Fang X; He L; Shao Y; Guo N; Wang L; Liu M; Li D; Geng H
Curr Mol Med; 2018; 18(7):436-447. PubMed ID: 30539697
[TBL] [Abstract][Full Text] [Related]
9. In vivo base editing rescues primary hyperoxaluria type 1 in rats.
Chen Z; Zhang D; Zheng R; Yang L; Huo Y; Zhang D; Fang X; Li Y; Xu G; Li D; Geng H
Kidney Int; 2024 Mar; 105(3):496-507. PubMed ID: 38142039
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-mediated metabolic pathway reprogramming in a novel humanized rat model ameliorates primary hyperoxaluria type 1.
Zheng R; Li Y; Wang L; Fang X; Zhang J; He L; Yang L; Li D; Geng H
Kidney Int; 2020 Oct; 98(4):947-957. PubMed ID: 32464217
[TBL] [Abstract][Full Text] [Related]
11. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter.
Hatch M; Gjymishka A; Salido EC; Allison MJ; Freel RW
Am J Physiol Gastrointest Liver Physiol; 2011 Mar; 300(3):G461-9. PubMed ID: 21163900
[TBL] [Abstract][Full Text] [Related]
12. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology.
Estève J; Blouin JM; Lalanne M; Azzi-Martin L; Dubus P; Bidet A; Harambat J; Llanas B; Moranvillier I; Bedel A; Moreau-Gaudry F; Richard E
Biochem Biophys Res Commun; 2019 Oct; 517(4):677-683. PubMed ID: 31402115
[TBL] [Abstract][Full Text] [Related]
13. Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations.
Kanoun H; Jarraya F; Maalej B; Lahiani A; Mahfoudh H; Makni F; Hachicha J; Fakhfakh F
BMC Nephrol; 2017 Oct; 18(1):303. PubMed ID: 28969594
[TBL] [Abstract][Full Text] [Related]
14. Identification of new mutations in primary hyperoxaluria type 1 (PH1).
von Schnakenburg C; Rumsby G
J Nephrol; 1998; 11 Suppl 1():15-7. PubMed ID: 9604803
[TBL] [Abstract][Full Text] [Related]
15. Human MiR-4660 regulates the expression of alanine-glyoxylate aminotransferase and may be a biomarker for idiopathic oxalosis.
Tu X; Zhao Y; Li Q; Yu X; Yang Y; Shi S; Ding Z; Miao Y; Zou Z; Wang X; Jiang J; Du D
Clin Exp Nephrol; 2019 Jul; 23(7):890-897. PubMed ID: 30852714
[TBL] [Abstract][Full Text] [Related]
16. Gly161 mutations associated with Primary Hyperoxaluria Type I induce the cytosolic aggregation and the intracellular degradation of the apo-form of alanine:glyoxylate aminotransferase.
Oppici E; Roncador A; Montioli R; Bianconi S; Cellini B
Biochim Biophys Acta; 2013 Dec; 1832(12):2277-88. PubMed ID: 24055001
[TBL] [Abstract][Full Text] [Related]
17. ATP-dependent degradation of a mutant serine: pyruvate/alanine:glyoxylate aminotransferase in a primary hyperoxaluria type 1 case.
Nishiyama K; Funai T; Yokota S; Ichiyama A
J Cell Biol; 1993 Dec; 123(5):1237-48. PubMed ID: 8245128
[TBL] [Abstract][Full Text] [Related]
18. Effect of alanine supplementation on oxalate synthesis.
Wood KD; Freeman BL; Killian ME; Lai WS; Assimos D; Knight J; Fargue S
Biochim Biophys Acta Mol Basis Dis; 2021 Jan; 1867(1):165981. PubMed ID: 33002578
[TBL] [Abstract][Full Text] [Related]
19. A Putative Mutation Hotspot of the AGXT Gene Associated with Primary Hyperoxaluria Type 1 in the Chinese Population.
Li X; Gu J; Yang Y; Li J; Li Y
Tohoku J Exp Med; 2018 Dec; 246(4):233-241. PubMed ID: 30541997
[TBL] [Abstract][Full Text] [Related]
20. Molecular etiology of primary hyperoxaluria type 1: new directions for treatment.
Danpure CJ
Am J Nephrol; 2005; 25(3):303-10. PubMed ID: 15961951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
